



**MEMORANDUM OF UNDERSTANDING  
BETWEEN  
THE WORLD MEDICAL ASSOCIATION (WMA)  
AND  
THE INTERNATIONAL FEDERATION OF  
ASSOCIATIONS OF PHARMACEUTICAL PHYSICIANS (IFAPP)**

The purpose of this Memorandum of Understanding (MOU) is to facilitate and stimulate contacts and co-operation between the World Medical Association, hereinafter referred to as „WMA“ and the International Federation of Associations of Pharmaceutical Physicians hereinafter referred to as „IFAPP“, on all projects of common concern that could be launched in the future.

Considering that the mission of the WMA, as a neutral and independent global federation of National Medical Associations representing physicians worldwide, is to act on behalf of patients and physicians. Considering that the WMA endeavours to achieve the highest possible standards of medical care, ethics, education and health-related human rights for all people.

Taking into account that the mission of IFAPP is to promote Pharmaceutical Medicine by enhancing the knowledge, expertise and skills of pharmaceutical physicians world-wide, thus leading to the availability and appropriate use of medicines for the benefit of patients and the society.

Recognizing the need for facilitating co-ordination and implementation of common projects about the role of physicians in the development, testing and monitoring of pharmaceuticals and medicinal products, the global participation of professionals in the pharmaceutical research and development, the ethical conduct of physicians in these efforts and the maintenance of their professional autonomy to protect the safety and dignity of patients and other research subjects.

**The WMA and the IFAPP have agreed to the following:**

**Article 1. Reciprocal representation.**

Each organisation will invite the other party to participate as an observer in its meetings where matters of mutual interest may arise, and make the reports of these meetings available.

The WMA will invite IFAPP to send a representative to participate without voting rights at the General Assembly of the WMA as well as at other meetings of common interest. The representative of IFAPP will have the opportunity to address the General Assembly or give a presentation on request. The details of the scheduling of any such intervention will be determined by the chairperson of the respective assembly or session.

Likewise, IFAPP will also invite a representative of the WMA (through the Secretary General of the WMA) to participate in, or be represented at, without voting rights, the General Assembly of the IFAPP as well as at other meetings of common interest where the representative of the WMA, will have the opportunity to address the assembly or meeting of IFAPP or to give a presentation on request. The details of the scheduling of any such intervention will be determined by the chairperson of the respective assembly or session.

**Article 2. Exchange of information and documents.**

Subject to any arrangements which may be necessary to safeguard the confidentiality of certain documents, the WMA and the IFAPP may exchange technical documents, that can be distributed among the members of both organizations.

Ownership of such information shall remain with the party that provides it unless otherwise stated. Any publication or sharing beyond the organization can only be made with the agreement of the document owner.

**Article 3. Co-operation.**

The WMA and the IFAPP on an organizational level agree to co-operate and consult each other on questions of mutual interest, in particular those concerning pharmaceutical medicine, especially the development and testing of new pharmaceuticals and the ethical rules of such.

The WMA and the IFAPP may agree on joint projects, notably in the field of pharmaceutical medicine and medical ethics.

**Article 4. Validity and duration.**

The present memorandum of understanding will enter into force once signed by both parties and shall be of indefinite duration.

Either party may propose written amendments to this MOU which, upon written agreement of the other party, shall be considered part of this MOU.

Either party may terminate this MOU at any time by an official notification giving to the other not less than three months' notice and stating the reasons for termination.

Signed in two original copies in English.  
Chicago, 14 October 2017

For the  
**World Medical Association**

For the  
**International Federation of  
Associations of Pharmaceutical Physicians**

**Otmar Kloiber**  
**Secretary General**

**Gustavo Kesselring**  
**International Affairs**

**Yoshitake Yokokura**  
**President**

**Honorio Silva**  
**President**